| ²é¿´: 436 | »Ø¸´: 2 | |||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õ߻ƻÆ516½«ÔùËÍÄú 5 ¸ö½ð±Ò | |||
[ÇóÖú]
Blood ¹ØÓÚZUMA7Ñо¿½á¹û
|
|||
|
Âé·³°ïæÕÒÒ»ÏÂÔÎÄ ·¢×ÔСľ³æIOS¿Í»§¶Ë |
» ²ÂÄãϲ»¶
RY£ºÖйú²ú³öµÄ¿ÆÑ§À¬»øÂÛÎÄ£¬¾ø¶ÔÊýÁ¿ºÍ±ÈÀý¶¼ÊÀ½çµÚÒ»
ÒѾÓÐ16È˻ظ´
297£¬¹¤¿Æµ÷¼Á?ºÓÄÏũҵ´óѧ±¾¿Æ
ÒѾÓÐ7È˻ظ´
ҩѧÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
ʳƷÓëÓªÑø£¨0955£©271Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
366Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
085408¹âµçÐÅÏ¢¹¤³Ìר˶355Ò»Ö¾Ô¸³¤´º¹â»úËùµ÷¼Á
ÒѾÓÐ13È˻ظ´
һ־Ը³¶«´óѧ071000ÉúÎïѧѧ˶³õÊÔ·ÖÊý276Çóµ÷¼Á
ÒѾÓÐ25È˻ظ´
ҩѧ305Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
ת³¤Æ¸ÁË
ÒѾÓÐ6È˻ظ´
22408 312Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
|
Blood. 2022 Nov 24;140(21):2248-2260Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma ·¢×ÔСľ³æIOS¿Í»§¶Ë |
2Â¥2024-01-23 10:21:49
3Â¥2024-01-23 10:22:09














»Ø¸´´ËÂ¥